Table 2.
Treatment continuation patient numbers among those who agreed to start treatment.
Drug chosen | Bone status | Start | 6th month | 12th month |
---|---|---|---|---|
Raloxifene | Osteoporosis | 31 | 16 (51.6%) | 14 (45.2%) |
Alendronate | Osteoporosis | 155 | 99 (63.9%) | 91 (58.7%) |
Alendronate | Osteopenia, high risk | 72 | 35 (48.6%) | 28 (38.9%) |
Denosumab | Osteoporosis | 5 | 5 (100%) | 5 (100%) |